Hepatic Disposition of Fexofenadine: Influence of the Transport Inhibitors Erythromycin and Dibromosulphothalein
- 128 Downloads
Purpose. To examine the disposition of fexofenadine in the isolated perfused rat liver and the influence of erythromycin and dibromosulphthalein (DBSP) on the hepatic uptake and biliary excretion of fexofenadine.
Methods. Livers from four groups of rats were perfused in a recirculatory manner with fexofenadine HCl added as a bolus (125, 250, 500, or 1000 μg) to perfusate. Livers from another three groups of rats were perfused with 250 μg of fexofenadine HCl. With one group as control, erythromycin (4.0 μg/ml) or DBSP (136 μg/ml) was added to the perfusate of the other groups. In all experiments, perfusate and bile were collected for 60 min; in addition, livers from the second experiment were retained for assay. Fexofenadine was determined in perfusate, bile, and homogenized liver by HPLC.
Results. The area under the curve (AUC) of fexofenadine was linearly related to concentration. It was unchanged from control (12,800 ± 200 ng·h/ml) by erythromycin (14,400 ± 2000 ng·h/ml), but was increased 95% by DBSP (25,000 ± 2600 ng·h/ml, P <0.001). The ratios of the concentrations of fexofenadine in liver/perfusate were decreased significantly by DBSP; those for bile/liver were increased by erythromycin.
Conclusions. Erythromycin reduced the canalicular transport of fexofenadine into bile, whereas DBSP reduced uptake across the sinusoidal membrane.
Unable to display preview. Download preview PDF.
- 1.T. Russell, M. Stoltz, and S. Weir. Pharmacokinetics, pharmacodynamics, and tolerance of single-and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin. Pharmacol. Ther. 64:612–621 (1998).Google Scholar
- 2.C. M. Pratt, J. Mason, T. Russell, R. Reynolds, and R. Ahlbrandt. Cardiovascular safety of fexofenadine HCl. Am. J. Cardiol. 83: 1451–1454 (1999).Google Scholar
- 3.C. Lippert, J. Ling, P. Brown, S. Burmaster, M. Eller, L. Cheng, R. Thompson, and S. Weir. Mass balance and pharmacokinetics of MDL 16,455A in healthy male volunteers. Pharm. Res. 13(suppl. 9):S-390 (1996).Google Scholar
- 4.K. T. Kivisto, P. J. Neuvonen, and U. Klotz. Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clin. Pharmacokinet. 27:1–5 (1994).Google Scholar
- 5.P. K. Honig, D. C. Wortham, R. Hull, K. Zamani, J. E. Smith, and L. R. Cantilena. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J. Clin. Pharmacol. 33:1201–1206 (1993).Google Scholar
- 6.P. K. Honig, D. C. Wortham, K. Zamani, J. C. Mullin, D. P. Conner, and L. R. Cantilena. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiac pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 53:630–636 (1993).Google Scholar
- 7.M. Takano, R. Hasegawa, T. Fukuda, R. Yumoto, J. Nagai, and T. Murakami. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur. J. Pharmacol. 358:289–294 (1998).Google Scholar
- 8.R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. J. Wood, and G. R. Wilkinson. Interrelationship between substrates and inhibitors of human CYP3A and Pglycoprotein. Pharm. Res. 16:408–414 (1999).Google Scholar
- 9.A. Soldner, U. Christians, M. Susanto, V. J. Wacher, J. A. Silverman, and L. Z. Benet. Grapefruit juice exerts stimulatory effects on P-glycoprotein. Clin. Pharmacol. Ther. 65:205 (1999).Google Scholar
- 10.M. Cvetkovic, B. Leake, M. F. Fromm, G. R. Wilkinson, and R. B. Kim. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27:866–871 (1999).Google Scholar
- 11.M. Müller and P. L. M. Jansen. Molecular aspects of hepatobiliary transport. Am. J. Physiol. 272:G1285–G1303 (1997).Google Scholar
- 12.H. M. J. Nijssen, T. Pijning, D. K. F. Meijer, and G. M. M. Groothuis. Mechanistic aspects of uptake and sinusoidal efflux of dibromosulfophthalein in the isolated perfused rat liver. Biochem. Pharmacol. 42:1997–2002 (1991).Google Scholar
- 13.Approved Product Information. Telfast Capsules. Hoechst Marion Roussel, Lane Cove, Australia.Google Scholar
- 14.A. M. Evans and K. Shanahan. The disposition of morphine and its metabolites in the in-situ rat isolated perfused liver. J. Pharm. Pharmacol. 47:333–339 (1995).Google Scholar
- 15.R. A. Okerholm, D. L. Weiner, R. H. Hook, B. J. Walker, G. A. Leeson, S. A. Biedenbach, M. J. Cawein, T. D. Dusebout, and G. J. Wright. Bioavailability of terfenadine in man. Biopharm. Drug Dispos. 2:185–190 (1981).Google Scholar
- 16.D. A. Garteiz, R. H. Hook, B. J. Walker, and R. A. Okerholm. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung 32:1185–1190 (1982).Google Scholar
- 17.P. K. Honig, R. L. Woosley, K. Zamani, D. P. Conner, and L. R. Cantilena. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52:231–238 (1992).Google Scholar
- 18.P. K. Honig, D. C. Wortham, K. Zamani, D. P. Conner, J. C. Mullin, and L. R. Cantilena. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513–1518 (1993).Google Scholar
- 19.C. D. Klaassen and G. L. Plaa. Hepatic disposition of phenoldibromphthalein disulfonate and sulfobromophthalein. Am. J. Physiol. 215:971–976 (1986).Google Scholar
- 20.M. Yamazaki, H. Suzuki, Y. Sugiyama, T. Iga, and M. Hanano. Uptake of organic anions by isolated rat hepatocytes. A classification in terms of ATP-dependency. J. Hepatol. 14:41–47 (1992).Google Scholar
- 21.H. Kouzuki, H. Suzuki, B. Stieger, P. J. Meier, and Y. Sugiyama. Characterization of the transport properties of organic anion transporting polypeptide 1 (oatp1) and Na+/taurocholate cotransporting polypeptide (Ntcp): comparative studies on the inhibitory effects of their possible substrates in hepatocytes and cDNA-transfected COS-7 cells. J. Pharmacol. Exp. Ther. 292: 505–511 (2000).Google Scholar
- 22.K. Sathirakul, H. Suzuki, T. Tamada, M. Hanano, and Y. Sugiyama. Multiple transport systems for organic anions across bile canalicular membrane. J. Pharmacol. Exp. Ther. 268:65–73 (1994).Google Scholar
- 23.A. Blom, A. H. J. Scaf, and D. K. F. Meijer. Hepatic drug transport in the rat. A comparison between isolated hepatocytes, the isolated perfused liver and the liver in vivo. Biochem. Pharmacol. 31:1553–1565 (1982).Google Scholar
- 24.R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter Pglycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289–294 (1998).Google Scholar
- 25.J. D. Whisnant, G. H. Hurst, and K. I. R. Brouwer. Fexofenadine (Fex) disposition in the isolated perfused rat liver (IPL): effects of ketoconazole (Ket) and erythromycin (Ery). Pharm. Res. 14(suppl.):S-560 (1997).Google Scholar
- 26.E. G. Scheutz, K. Yasuda, K. Arimori, and J. D. Scheutz. Human MDR1 and mouse mdr1 P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid and benzo(a)pyrene. Arch. Biochem. Biophys. 350:340–347 (1998).Google Scholar
- 27.D. J. Birkett, R. A. Robson, N. Grgurinovich, and A. Tonkin. Single dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Ther. Drug Monitoring 12:65–71 (1990).Google Scholar
- 28.M. M. Gottesman and I. Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385–427 (1993).Google Scholar